APLT News and Press, Applied Therapeutics Inc. From 09/28/23

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM) Baseline data from ARISE-HF shows patients with DbCM exhibit reduced cardiac functional capacity resulti...

2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...

2023-09-19 13:01:28 ET Gainers: Connexa Sports Technologies ( CNXA ) +170% . Davis Commodities Limited Ordinary Shares ( DTCK ) +83% . Maplebear ( CART ) +40% . Avinger ( AVGR ) +40% . Rackspace Technology ( RXT ) +37% . Elut...

Applied Therapeutics, Inc. (NASDAQ: APLT) is one of today's top gainers. The company's shares are currently up 22.76% on the day to $2.43. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabeti...

2023-09-06 12:53:35 ET Gainers: NeuBase Therapeutics ( NBSE ) +124% . Palisade Bio ( PALI ) +113% . Power REIT ( PW ) +45% . AeroVironment ( AVAV ) +26% . Theratechnologies ( THTX ) +27% . iCoreConnect ( ICCT ) +20% ....

2023-09-06 10:00:10 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-06 09:17:41 ET More on Applied Therapeutics Seeking Alpha’s Quant Rating on Applied Therapeutics Historical earnings data for Applied Therapeutics Financial information for Applied Therapeutics Applied Therapeutics: Buy For Upcoming Pre-NDA Mee...

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced successful completion of...

2023-08-17 04:28:21 ET Summary Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potential. Despite missing the primary endpoint in galacto...

2023-08-10 12:25:36 ET Applied Therapeutics press release ( NASDAQ: APLT ): Q2 GAAP EPS of -$0.37. Cash and cash equivalents and short-term investments totaled $35.6 million as of June 30, 2023, compared with $30.6 million at December 31, 2022. For further details se...